In line with these results, in a mouse model of NSCLC with mutations on the p53 and KRAS genes was shown that administration of the NOS inhibitor L-NAME inhibited lung tumor growth, reduced tumor burden, and improved survival (Pershing et al., 2016). This evidence concerns the gene TP53 and non-small cell lung carcinoma.